<DOC>
	<DOCNO>NCT02842749</DOCNO>
	<brief_summary>To evaluate safety efficacy everolimus ( AfinitorÂ® ) Chinese adult patient local advance metastatic , well differentiate progressive pancreatic neuroendocrine tumor .</brief_summary>
	<brief_title>Phase IV Study Safety Efficacy Everolimus Adult Patients With Progressive pNET China</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must histological confirm G1 G2 pancreatic neuroendocrine tumor ( pNETs ) ( WHO 2010 ) Patients must radiological documentation progression disease per RECIST 1.1 within 12 month prior enrollment . Measurable disease per RECIST 1.1 criterion use triphasic compute tomography ( CT ) scan multiphase MRI radiologic assessment . everolimus treatment recommend treat physician Hypersensitivity everolimus , rapamycin derivative , excipients . Patient unwilling receive Afinitor treatment due reason . Pregnant nursing ( lactate ) woman , Prior therapy mTOR inhibitor ( e.g . sirolimus , temsirolimus , everolimus ) . Use investigational drug within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>